IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer

Journal of Immunology

Volumn 163, Issue 4, 1999, Pages 1923-1928

  Rodolfo, Monica ^a   Zilocchi, Chiara ^a   Accornero, Paola ^a   Cappetti, Barbara ^a   Arioli, Ivano ^a   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 4; TUMOR CELL VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOREGULATION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ADOPTIVE TRANSFER; ANIMALS; CANCER VACCINES; CARRIER PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CYTOKINES; FEMALE; GENE TRANSFER TECHNIQUES; GRANULOCYTES; INTERLEUKIN-4; KILLER CELLS, NATURAL; LONGEVITY; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, CELL SURFACE; RETROVIRIDAE; T-LYMPHOCYTE SUBSETS;

EID: 0033566935     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Musiani, P., A. Modesti, M. Giovarelli, F. Cavallo, M. P. Colombo, P. L. Lollini, and G. Forni. 1997. Cytokines, tumor-cell death and immunogenicity: a question of choice. Immunol. Today 18:32.
2. Paul, W. E. 1991. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 77:1859.
3. O'Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subset. Immunity 8:275.
4. Tepper, R. I., P. K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503.
5. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, and D. M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
6. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to produce IL-4. J. Inmunol. 153:5659.
7. Stoppacciaro, A., P. Paglia, L. Lombardi, G. Parmiani, C. Baroni, and M. P. Colombo. 1997. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur. J. Immunol. 27:2375.
8. Tepper, R.I., R. L. Coffman, and P. Leder. 1992. An eosiphil-dependent mechanism for the antitumor effect of IL-4. Science 257:548.
9. Noffz, G., Z. Qin, M. Kopf, and T. Blankenstein. 1998. Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. J. Immunol. 160:345.
10. Hock, H., M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamantstein, and T. Blankenstein. 1993. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or Interferon γ. Proc. Natl. Acad. Sci. USA 90:2774.
11. Allione, A., M. Consalvo, P. Nanni, P. L. Lollini, F. Cavallo, M. Giovarelli, M. Forni, A. Gulino, M. P. Colombo, P. Dellabona, et al. 1994. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-10. TNFα, GM-CSF, and γ-IFN gene or admixed with conventional adjuvants. Cancer Res. 54: 6022.
12. Lotze, M. T., J. T. Rubin, S. Carty, H. Edington, P. Ferson, R. Landreneau, B. Pippin, M. Posner, D. Rosenfelder, C. Watson, et al. 1994. Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum. Gene Ther. 5:41.
13. Cascinelli, N., R. Foa, G. Parmiani, F. Arienti, F. Belli, M. G. Bernengo, C. Clemente, M. P. Colombo, A. Guarini, M. T. Illeni, et al. 1994. Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells: a phase I-II study. Hum. Gene Ther. 5:1059.
14. Rodolfo, M., C. Melani, C. Zilocchi, B. Cappetti, E. Luison, I. Arioli, M. Parenza, S. Canevari, and M. P. Colombo. 1998. IgG2a induced by IL-12-producing tumor cell vaccines but not IgG1 induced by IL-4-vaccine is associated with the eradication of experimental metastases. Cancer Res. 58:5812.
15. Rodolfo, M., C. Zilocchi, B. Cappetti, I. Arioli, G. Parmiani, and M. P. Colombo. 1996. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens: comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J. Immunol. 157:5536.
16. Rodolfo, M., C. Zilocchi, B. Cappetti, G. Parmiani, C. Melani, and M. P. Colombo. 1999. Cytotoxic T lymphocyte response against a subdominant, non-immunoselected tumor antigen predicts the outcome of gene therapy with IL-12-transduced tumor vaccine. Gene Ther. 6:865.
17. Tsung, K., J. B. Meko, G. R. Peplinski, Y. L. Tsung, and J. A. Norton. 1997. IL-12 induces T helper I-directed antitumor response. J. Immunol. 158:3359.
18. Carter, L. L., and R. W. Dutton. 1996. Type I and type 2: a fundamental dichotomy for all T-cell subsets. Curr. Opin. Immunol. 8:336.
19. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more, Immunol. Today 17:138.
20. Croft, M., L. Carter, S. L. Swain, and R. W. Dutton. 1994. Generation of polarized antigen-specific CD8 effector populations, reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180:1715.
21. + T cells: their activation and effector functions. Curr. Opin. Immunol. 6:453.
22. + T cells secreting Th1 or Th2 cytokines. Immunity 2:271.
23. Cerwenka, A., L. L. Carter, J. B. Reome, S. L. Swain, and R. W. Dutton. 1998. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines. J. Immunol. 161:97.
24. + T cells that secrete IFN-γ and IL-5. J. Immunol. 145:68.
25. + T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J. Immunol. 158:3539.
26. Salgame, P., J. S. Abrams, C. Clayberger, H. Goldstein, J. Convit, R. L. Modlin, and B. R. Bloom. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279.
27. + T helper type 2 cells. J. Exp. Med. 181:5.
28. + T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type I infection. J. Exp. Med. 180:489.
29. + T cell clones can provide B cell help. J. Immunol. 154:3118.
30. Li. L., S. Sad, D. Kagi, and T. R. Mosmann. 1997. CD8 Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions. J. Immunol. 158:4152.
31. + and their role in the generation of antigen-specific cytotoxic T cells. Eur. J. Immunol. 21:1863.
32. Sander, B., I. Hoiden, U. Andersson, E. Moller, and J. S. Abrams. 1993. Similar frequencies and kinetics of cytokine producing cells in murine peripheral blood and spleen: cytokine detection by immunoassay and intracellular immunostaining. J. Immunol. Methods 166:201.
33. Yoshizawa, H., A. E. Chang, and S. Y. Shu. 1991. Specific adoptive immunotherapy mediated by tumor-draining lymph node sequentially activated with anti-CD3 and IL-2. J. Immunol. 147:729.
34. - T cells: tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161: 1122.
35. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J. Immunol. 146:3235.
36. + T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity. Blood 89:2529.
37. + T cells, infusional IL-2, and cyclophosphamide in patients with advanced cancer. J. Clin. Oncol. 16:2752.
38. Goedegebuure, P. S., M. Zuber, D. L. Leonard-Vidal, U. L. Burger, J. C. Cusack, Jr., M. P. Chang, L. M. Douville, and T. J. Eberlein. 1994. Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg. Oncol. 3:79.
39. Krauss, J. C., S. E. Strome, A. E. Chang, and S. Shu. 1994. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4. J. Immunother. 16:77.
40. + cytotoxic T lymphocyte activation in mice. Cancer Res. 56:5005.
41. Widmer, M. B., and K. H. Grabstein. 1987. Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor. Nature 326:795.
42. Corrigan, C. J., and A. B. Kay. 1992. T cells and eosinophils in the pathogenesis of asthma. Immunol. Today 13:501.
43. Naume, B., R. Shalaby, W. Lesslauer, and T. Espevik. 1991. Involvement of the 55-and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J. Immunol. 146:3045.
44. + T lymphocyte migration. J. Immunol. 151:4545.
45. Clerici, M., G. M. Shearer, and E. Clerici. 1998. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasia: time to consider the TH1/ TH2 paradigm. J. Natl. Cancer Inst. 90:287.
46. Laman, J. D., E. J. Thompson, and L. Kappos. 1998. Balancing the Th1/Th2 concept in multiple sclerosis. Immunol. Today 18:489.
47. Murphy, W. J., L. A. Welniak, D. D. Taub, R. H. Wiltrout, P. A. Taylor, D. A. Vallera, M. Kopf, H. Young, D. L. Longo, and B. R. Blazar. 1998. Differential effects of the absence of interferon y and IL-4 in acute graft-versus host disease after allogeneic bone marrow tranplantation in mice. J. Clin. Invest. 102: 1742.
48. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
49. Marchand, M., P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet et al. 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63:883.
50. Arienti, F., J. Sulé-Suso, F. Belli, L. Mascheroni, L. Rivoltini, C. Melani, M. Maio, N. Cascinelli, M. P. Colombo, and G. Parmiani. 1996. Limited anti-tumor T cell response in melanoma patients vaccinated with IL-2 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 7:1955.
51. Arienti, F., F. Belli, F. Napolitano, J. Sulé-Suso, A. Mazzocchi, G. F. Gallino, A. Cattelan, C. Sanantonio, L. Rivoltini, C. Melani, et al. 1999. Vaccination of melanoma patients with IL-4 gene-transduced allogenic melanoma cells. Hum. Gene Ther. In press.